Navigation Links
Seattle Genetics Highlights Data on its Proprietary Antibody-Drug,Conjugate Technology at AACR

BOTHELL, Wash. & LOS ANGELES--(BUSINESS WIRE)--Apr 17, 2007 - Seattle Genetics, Inc. (Nasdaq: SGEN) today announced data from fifteen presentations by the company and its collaborators at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) demonstrating preclinical advances with its proprietary antibody-drug conjugate (ADC) technology and cancer product pipeline.

ADCs are monoclonal antibodies linked to cell-killing drugs. Seattle Genetics' ADC technology employs synthetic, highly potent drugs that are bound to monoclonal antibodies through proprietary linker systems. The linkers are designed to be stable in the bloodstream but to release the drug payload under specific conditions once inside target cells, thereby sparing non-target cells many of the toxic effects of traditional chemotherapy.

"Empowered antibodies utilizing our ADC technology have the potential to significantly impact the way cancer is treated," said Clay B. Siegall, Ph.D., President and Chief Executive Officer at Seattle Genetics. "Our strong presence at AACR this year reflects continued progress with our proprietary and partnered ADC programs. We expect to report clinical data from the ongoing phase I dose-escalation trial of SGN-35, our lead ADC, later this year, while both we and our collaborators continue to advance additional ADC programs into and towards the clinic."

ADC Programs

Researchers reported preclinical data at AACR describing how changes in the structure of the attached drugs can affect ADC efficacy and tolerability, the impact that linker structure and these modifications can have on ADC activity, and the ability of Seattle Genetics' ADC technology to effectively deliver active drugs to target tissue while avoiding non-targeted drug release. (Abstracts #4793, #916 and #4088) Further data from preclinical models of ADCs provide mechanistic insight into how and when drugs are r
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
3. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
6. Myriad Genetics Presents Tumor Origin Technology at AACR
7. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
8. Myriad Genetics Presents Azixas Mode of Action at AACR
9. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
Post Your Comments:
(Date:5/27/2015)... -- LumiThera Inc., a developmental stage medical device company ... disorders and disease, announced today that they were ... Life Sciences Discovery Fund (LSDF) commercialization grant. LumiThera was ... grants worth $500,000 to provide for commercialization activities ... macular degeneration (AMD). LSDF executive ...
(Date:5/27/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/nt9zlx/asia_pacific ) has announced the ... Growth, Trends And Forecasts (2014 - 2019)" company ... detailed type of imaging that customs a low-dose x-ray ... mammogram, is used to support in the early detection ... (radiograph) is a noninvasive medical test that helps physicians ...
(Date:5/27/2015)... 2015 The report " Tube Packaging Market ... Oral Care, Food & beverages, Pharmaceuticals, Consumer Goods), by Material ... - Trends & Forecasts to 2020", published by MarketsandMarkets, The ... a CAGR of 6.65% from 2015, to reach $8,638.9 Million ... Tables and   61 F igures spread thro ...
Breaking Medicine Technology:LumiThera Receives LSDF Commercialization Grant Award 2Asia Pacific Mammography Market Trends and Forecasts 2015-2019 2Tube Packaging Market Worth $8.63 Billion by 2020 2Tube Packaging Market Worth $8.63 Billion by 2020 3Tube Packaging Market Worth $8.63 Billion by 2020 4
... IRVINE, Calif., Feb. 22, 2011 ResearchDx announced ... Diagnostics Organization or CDO. Recent ... and the Drug-Diagnostic Co-Development Concept Paper, have spurred ... purpose of developing companion diagnostics. The traditional Contract ...
... Enox Biopharma, Inc. CEO, John C. Rewcastle, Ph.D., will present ... February 24 at 11:05 AM PST. The conference is being ... Dr. Rewcastle will provide an overview of Enox,s technology ... devices rendering them antimicrobial. He will also review recently published ...
Cached Medicine Technology:ResearchDx Launches Contract Diagnostics Organization (CDO) 2Enox Biopharma, Inc. to Present at IN3 West Investment in Innovation Conference. 2
(Date:5/27/2015)... In today's healthcare landscape, where costs ... be challenging for doctors and hospitals to keep up ... , Austin-based HealthTronics, Inc. is offering a ... therapies for clinically sophisticated applications. The company has now ... Laser Ventures, Inc ., a mobile laser technology ...
(Date:5/27/2015)... 2015 Dr. Omar Ibrahimi, Dermatologist and ... CT has been selected as part of a controlled ... (and the only physician in Connecticut) to offer the ... the removal of submental fat (double chin). The procedure ... no surgery and minimal risks. Dr. Ibrahimi is an ...
(Date:5/27/2015)... NOVAtime Technology, Inc. ( http://www.novatime.com ), a ... organizations, announced today that SanMar Corporation successfully implemented ... attendance and point tracking processes for over 3,000 ... , Family-owned since 1971, Seattle-based SanMar Corporation ... label, and mill brands. SanMar supplies apparel and ...
(Date:5/27/2015)... 2015 In support of a ... of the Journal of American Geriatrics Society about the ... Bedford Commons OB-GYN P.A . is reiterating the ... beverages. , To examine the relationship between diet ... Antonio Longitudinal Study of Aging (SALSA) tracked the soda ...
(Date:5/27/2015)... 2015 The Case Management Society ... to provide CMSA's Career and Knowledge Pathways educational ... to strengthen the case/care management workforce by offering ... The mutually beneficial agreement provides Medix, a workforce ... talent in the healthcare, scientific and IT industries, ...
Breaking Medicine News(10 mins):Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 2Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 3Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 3Health News:SanMar Corporation Successfully Implemented NOVAtime Workforce Management Solution across 9 locations 2Health News:SanMar Corporation Successfully Implemented NOVAtime Workforce Management Solution across 9 locations 3Health News:Recent Study About the Link Between Diet Sodas and Abdominal Fat Reinforces Bedford Commons OB-GYN's Recommendation to Drink Plenty of Water 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 3
... Luminex Corporation,(Nasdaq: LMNX ) today announced that ... to be held September 24-27, 2007, in New,York City. ... and chief,executive officer, and Harriss T. Currie, chief financial ... September 24, 2007. The,presentation will be webcast live and ...
... BEDFORD, Mass., Sept. 19 Hologic, Inc.,(Nasdaq: HOLX ... be presenting at the UBS Global Life Sciences Conference ... Hyatt Hotel in New York, NY. Interested parties ... of,Hologic,s investor presentation on Wednesday, September 26, 2007 at ...
... Sept. 19 Statement by Chris,Cathcart, President, CSPA: ... the report issued by the Natural Resources,Defense Council ... of air,freshener products. NRDC,s report appears to be ... unit each of 14 air freshener products. As ...
... of parents feel they play a significant role in ... at the University of Michigan C.S. Mott Childrens Hospital. ... issue of the Journal of Pediatrics, 86 percent of ... their hospitalized childs medical care. Researchers also found that ...
... is one of four oral medications approved by ... the treatment of alcoholism. A recent large ... the National Institute of Alcoholism and Alcohol Abuse ... a modest but significant benefit but another FDA-approved ...
... (H 2 S) directly into the heart during a ... damage often seen in oxygen-starved organs, according to a ... at Birmingham. , H 2 S boosts post-heart-attack function ... effect of restoring blood flow swiftly to hearts suffering ...
Cached Medicine News:Health News:Luminex Corporation To Present at UBS Global Life Sciences Conference 2Health News:Consumer Specialty Products Association Highly Critical of NRDC Study on Home Air Fresheners 2Health News:Parents' participation in medical decisions linked to self-efficacy 2Health News:Family history of alcoholism affects response to drug used to treat heavy drinking 2Health News:Severe heart attack damage limited by hydrogen sulfide 2
Shahinian lacrimal cannula, bullet shaped tip, 0.3 mm side opening, straight....
Button Tip Manipulator, 0.50 mm diameter button tip, angled 45 degrees, 15 mm from tip to bend....
Round serrated handle, polished finish, overall length 130 mm....
Overall length 355 mm, 14.0 inches....
Medicine Products: